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Abstract: Gene expression studies of molar pregnancy have been limited to a small number of
candidate loci. We analyzed high-dimensional RNA and protein data to characterize molecular
features of complete hydatidiform moles (CHMs) and corresponding pathologic pathways.
CHMs and first trimester placentas were collected, histopathologically examined, then flash-frozen or
paraffin-embedded. Frozen CHMs and control placentas were subjected to RNA-Seq, with resulting
data and published placental RNA-Seq data subjected to bioinformatics analyses. Paraffin-embedded
tissues from CHMs and control placentas were used for tissue microarray (TMA) construction,
immunohistochemistry, and immunoscoring for galectin-14. Of the 14,022 protein-coding genes
expressed in all samples, 3,729 were differentially expressed (DE) in CHMs, of which 72% were
up-regulated. DE genes were enriched in placenta-specific genes (OR = 1.88, p = 0.0001), of which
79% were down-regulated, imprinted genes (OR = 2.38, p = 1.54 × 10−6), and immune genes
(OR = 1.82, p = 7.34 × 10−18), of which 73% were up-regulated. DNA methylation-related enzymes
and histone demethylases were dysregulated. “Cytokine–cytokine receptor interaction” was the
most impacted of 38 dysregulated pathways, among which 17 were immune-related pathways.
TMA-based immunoscoring validated the lower expression of galectin-14 in CHM. In conclusion,
placental functions were down-regulated, imprinted gene expression was altered, and immune
pathways were activated, indicating complex dysregulation of placental developmental and immune
processes in CHMs.
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1. Introduction
Gestational trophoblastic disease (GTD) is characterized by abnormal trophoblastic proliferation
and includes hydatidiform mole (complete and partial) and gestational trophoblastic neoplasia (invasive
mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor) [1,2].
Diagnosis relies on clinical presentation and histologic assessment, and treatment is aimed at uterine
evacuation with chemotherapy typically reserved for gestational trophoblastic neoplasia (GTN) [2,3].
Post-molar human chorionic gonadotropin (hCG) monitoring is an essential part of management for
evaluating the development of GTN, which follows complete hydatidiform moles (CHMs) in ~15–20%
of cases [4]. Although GTN is considered among the most curable of all solid tumors with cure
rates over 90%, unrecognized and misdiagnosed GTD can result in unnecessarily increased maternal
morbidity and mortality [3].
The reported incidence of GTD varies by geographic location, race or ethnicity, maternal age,
and histopathologic subtype. Hydatidiform mole reportedly complicates up to two per 1000 pregnancies
in Southeast Asia and Japan, nearly twice that proportion reported in North America, Australia,
New Zealand, and Europe [5]. This geographic variation has been partially attributed to racial and
ethnic differences, as the prevalence of GTD is elevated in American Indians, Asians, and Hispanics
across the world [6,7]. Asian and American Indian women have also been shown to have more
aggressive disease, with increased risk of developing GTN compared to other ethnic groups [8,9].
Extremes of maternal age are also correlated with higher rates of CHMs, with an increased incidence
among women over 40 years of age and under 20 years of age [10]. Beyond maternal age and ethnicity,
prior GTD is the strongest risk factor for GTD, with an incidence of 1.3% [11].
These described risk factors (race/ethnicity and prior GTD) are in accord with an underlying genetic
etiology of GTD [1,2,12]. The pathophysiology of hydatidiform moles involves overrepresentation of
the paternal genome. The biparental diandric triploid karyotype of partial moles accords with dispermic
fertilization, while androgenetic diploid karyotype of most CHMs is consistent with monospermic or
dispermic fertilization. Recently, some women with recurrent androgenetic CHMs were shown to have
bi-allelic deleterious mutations in MEI1 (meiotic double-stranded break formation protein 1), TOP6BL
(type 2 DNA topoisomerase 6 subunit B-like), and REC114 (meiotic recombination protein REC114),
leading to meiotic double-strand break formation and extrusion of all maternal chromosomes [13].
Absence of maternal imprinting of gene expression in hydatidiform moles has also been observed in the
rare biparental hydatidiform moles due to NLRP7 (NLR family pyrin domain containing 7) or KHDC3L
(KH domain containing 3 like) mutations, suggesting a common endpoint of pathogenesis [12,14,15].
However, for the more common sporadic CHMs, little is known regarding mechanisms responsible for
either pathogenesis or progression to GTN.
The few targeted gene expression studies on molar tissue and a recent meta-analysis of these
studies showed that the main genes differentially expressed (DE) in molar tissues may be those
involved in villous trophoblast differentiation [16]. However, these findings were based on a limited
set of molecules, and these studies mostly targeted placenta- or trophoblast-specific transcripts that
were known to be differentially expressed during trophoblast differentiation. A more comprehensive
approach to identifying genes and pathways involved in the development of molar disease would be a
genome-wide gene expression analysis using either microarrays or RNA-Seq, followed by protein-level
validation of DE transcripts.
We sought to implement such a high-dimensional and systems biology approach, similar to
that used in our recent study on the pathophysiological processes in preeclampsia [17], to gain more
in-depth insight into CHM pathogenesis at RNA and protein levels. This high-dimensional, agnostic
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study is the first to evaluate gene expression levels in CHMs using RNA-Seq followed by protein
level validation of selected DE transcripts by immunostaining of tissue microarrays (TMA) and
immunoscoring. The aim of our study is to identify genes with expression levels that differ in molar
tissue from CHMs in comparison to placental chorionic tissue from uncomplicated pregnancies at
similar stages of gestation. More complete understanding of the molecular pathways perturbed in
CHMs may inform future efforts to improve procedures for early diagnosis and prognostication.
2. Results
2.1. The Transcriptome of First Trimester Placentas and CHMs
To evaluate absolute gene expression levels, mean expression values were calculated for both
groups from RNA-Seq count data by normalizing for housekeeping genes. The highest expression in
first trimester placentas was mostly detected for genes with placenta-specific or predominant placental
expression [17–19]. Indeed, the 20 most highly-expressed genes (Table 1) included genes previously
shown to have predominant placental (n = 2) or placenta-specific (n = 12) expression and unique
placental functions in humans. These encode hormones (CGA, chorionic gonadotrophin subunit
alpha, CSH1 and CSH2, chorionic somatomammotropin hormone 1 and 2), an estrogen synthesizing
enzyme (CYP19A1, cytochrome P450 family 19 subfamily A member 1), proteases (ADAM12, ADAM
metallopeptidase domain 12; KISS1, kisspeptin-1; PAPPA and PAPPA2, pregnancy-associated plasma
protein A and A2; TFPI2, tissue factor pathway inhibitor 2), and immune proteins (PSG3 and PSG4,
placenta-specific glycoprotein 3 and 4).
Table 1. Genes encoding the 20 transcripts most highly expressed in first trimester placentas.
Gene Symbol Entrez ID Base Mean lfcSE Log2 FC pFDR p-Value Control Mean
CGA 1081 164,079.45 0.63 0.07 0.93 0.91 155,778.30
FN1 2335 141,988.22 0.56 0.32 0.64 0.57 135,448.78
TFPI2 7980 125,046.51 0.58 −1.16 0.08 0.05 127,071.15
CSH1 1442 87,798.80 0.67 −4.58 0.00 0.00 93,037.03
EEF1A1 1915 84,023.14 0.15 −1.20 0.00 0.00 87,193.18
PEG10 23089 77,282.40 0.24 −1.74 0.00 0.00 82,299.13
CSH2 1443 61,726.09 0.81 −4.23 0.00 0.00 65,433.13
COL3A1 1281 60,159.32 0.29 −1.30 0.00 0.00 63,035.40
KISS1 3814 65,121.70 0.65 0.13 0.88 0.84 61,457.48
ADAM12 8038 44,435.52 0.35 −0.06 0.90 0.86 43,427.10
CYP19A1 1588 40,376.35 0.53 −1.27 0.03 0.02 41,478.58
SPP1 6696 37,734.38 0.41 −4.02 0.00 0.00 40,796.23
TGM2 7052 39,725.43 0.36 −0.36 0.39 0.31 39,553.03
PSG3 5671 38,487.88 0.51 −1.05 0.07 0.04 39,153.23
PAPPA 5069 35,537.55 0.59 −1.35 0.04 0.02 36,733.78
PSG4 5672 33,870.64 0.59 −3.17 0.00 0.00 36,069.85
COL4A1 1282 36,995.51 0.37 0.33 0.46 0.37 35,055.03
PAPPA2 60676 34,031.77 0.48 0.31 0.60 0.52 32,044.98
FBN2 2201 30,126.49 0.26 −1.57 0.00 0.00 31,930.00
ACTB 60 31,472.69 0.22 0.39 0.11 0.07 29,870.08
Placenta-specific genes are shown in bold blue. False discovery rate, pFDR; fold change, FC; log fold change
standard error, lfcSE.
In CHMs, the overall median gene expression levels were ~13% higher than in normal placentas
(control placentas: 337.7 vs. CHMs: 382.8). However, placenta-specific transcript levels were 23% lower
in CHMs than in normal placentas (placentas: 3,729.6 vs. CHMs: 3,044.3), reflected in a lower number
of placenta-specific genes (n = 8) among the 20 most highly-expressed transcripts (Table 2). In turn,
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the 20 most abundant transcripts in CHMs encode proteins with immune, hormone, and oxygen
transport functions (FSTL3, follistatin-like 3; HBA2, hemoglobin-alpha 2; HBB, hemoglobin-beta; IGF2,
insulin-like growth factor 2; LEP, leptin; PAEP, progestogen-associated endometrial protein).
Table 2. Genes encoding the 20 transcripts most highly expressed in complete hydatidiform moles.
Gene Symbol Entrez ID Base Mean lfcSE Log2 FC pFDR p-Value Control Mean CHM Mean
HBB * 3043 33,412.13 0.49 7.74 0.00 0.00 1,608.00 373,335.00
CGA 1081 164,079.45 0.63 0.07 0.93 0.91 155,778.30 189,408.50
FN1 2335 141,988.22 0.56 0.32 0.64 0.57 135,448.78 184,274.75
PAEP * 5047 7,444.75 0.96 7.11 0.00 0.00 545.88 95,119.25
KISS1 3814 65,121.70 0.65 0.13 0.88 0.84 61,457.48 78,481.00
GDF15 * 9518 24,551.03 0.58 1.70 0.01 0.00 19,462.58 73,765.25
TFPI2 7980 125,046.51 0.58 −1.16 0.08 0.05 127,071.15 66,657.75
IGF2 * 3481 26,174.25 0.22 1.20 0.00 0.00 23,075.75 60,786.25
HBA2 * 3040 5,986.27 0.56 4.95 0.00 0.00 1,590.28 52,014.25
COL4A1 1282 36,995.51 0.37 0.33 0.46 0.37 35,055.03 49,353.25
ADAM12 8038 44,435.52 0.35 −0.06 0.90 0.86 43,427.10 47,781.00
LEP * 3952 6,372.49 0.65 3.52 0.00 0.00 3,092.85 45,604.50
ACTB 60 31,472.69 0.22 0.39 0.11 0.07 29,870.08 45,004.50
PAPPA2 60676 34,031.77 0.48 0.31 0.60 0.52 32,044.98 44,734.75
EEF1A1 * 1915 84,023.14 0.15 −1.20 0.00 0.00 87,193.18 43,702.00
AHNAK 79026 25,150.93 0.24 0.66 0.01 0.01 23,452.63 43,214.25
CGB5 93659 18,949.99 0.70 1.13 0.16 0.11 16,161.30 40,758.75
FLT1 2321 19,476.41 0.32 0.96 0.01 0.00 17,411.10 38,701.00
FSTL3 * 10272 7,919.03 0.63 2.57 0.00 0.00 5,172.10 36,659.00
CGB3 * 1082 13,840.61 0.66 1.49 0.04 0.02 11,254.20 35,670.25
Placenta-specific genes are shown in bold blue. Differentially expressed genes are shown with asterisks. Complete
hydatidiform mole, CHM; false discovery rate, pFDR; fold change, FC; log fold change standard error, lfcSE.
2.2. Differential Gene Expression in CHMs
Among transcripts of 14,022 protein-coding genes analyzed with RNA-Seq, a total of 3,729 (27%)
were found to be DE in CHMs in comparison to normal first trimester placental tissues. Of these,
2,667 (72%) were up-regulated while 1,062 (28%) were down-regulated in CHM tissues (Supplementary
Table S1, Figure 1). Of note, there were seven genes with placenta-specific expression among the top 20
transcripts most down-regulated but not up-regulated in CHMs (Table 3).
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plotted higher on the y-axis. Dotted lines represent the thresholds used to select the differentially 
expressed (DE) genes: <−1 and >1 for the magnitude of differential expression and pFDR < 0.05 for 
statistical significance. According to these criteria, of the 3,729 DE transcripts, 2,667 were up-regulated 
(depicted with red), while 1,062 were down-regulated (depicted with blue) in molar tissues. 
Enrichment analysis revealed significant enrichment (OR = 1.88, p = 0.0001) of placenta-specific 
genes (Supplementary Table 2, Figure 2A) among DE genes. Of interest, 50 out of 63 (79%) placenta-
specific DE genes, found to be expressed mainly by the trophoblast, were down-regulated. Among 
functions of products of these genes were growth hormones (CSHL1, chorionic somatomammotropin 
hormone-like 1; CSH1, CSH2), immune response (LGALS14, lectin, galactoside-binding, soluble, 14; 
PSG4), cell attachment (EGFL6, EGF-like domain multiple 6; SMAGP, small cell adhesion 
glycoprotein; SVEP1, Sushi, Von Willebrand factor type A, EGF and pentraxin domain containing 
protein 1), coagulation and blood pressure regulation (AGTR1, angiotensin II receptor type 1; F13A1, 
coagulation factor XIII A chain), and cell differentiation and developmental processes (PAGE4, PAGE 
family member 4; PLAC1, placenta specific 1; RASA1, RAS P21 protein activator 1). 
  
Figure 1. Differ ntial gen pre sion in complete hydatidiform moles. All 14,022 expressed
protein-coding genes are represented in terms of their measured differences in transcript abundance
(x-axis) and the significance of the difference (y-axis) on a volcano plot. The significance is represented
as negative log (base 10) of the adjusted p-value so that more significant differences in expression are
plotted higher on the y-axis. Dotted lines represent the thresholds used to select the differentially
expressed (DE) genes: <−1 and >1 for the magnitude of differential expression and pFDR <0.05 for
statistical significance. According to these criteria, of the 3,729 DE transcripts, 2,667 were up-regulated
(depicted with red), while 1062 were down-regulated (depicted with blue) in molar tissues.
Enrichment analysis revealed significant enrichment (OR = 1.88, p = 0.0001) of placenta-specific
genes (Supplem tary Table S2, Figure 2A) among DE genes. Of interest, 50 out of
63 (79%) placenta-specific DE genes, found to be expressed ma nly by the trophoblast,
were down-regulated. Among functio s of roducts of these ge es were growth hormones (CSHL1,
chorionic somatomam otropin hormone-like 1; CSH1, CSH2), immune response (LGALS14, lectin,
galactoside-binding, soluble, 14; PSG4), cell attachment (EGFL6, EGF-like domain multiple 6; SMAGP,
small cell adhesion glycoprotein; SVEP1, Sushi, Von Willebrand factor type A, EGF and pentraxin
domain containing protein 1), coagulation and blood pressure regulation (AGTR1, angiotensin II
receptor type 1; F13A1, coagulation factor XIII A chain), and cell differentiation and developmental
processes (PAGE4, PAGE family member 4; PLAC1, placenta specific 1; RASA1, RAS P21 protein
activator 1).
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Table 3. Genes encoding the 20-20 transcripts with highest and lowest expression in complete
hydatidiform moles.
Gene Symbol Entrez ID Base Mean Log2 FC lfcSE p-Value pFDR
HBB 3043 33,412.13 7.74 0.49 4.64 × 10−57 4.06 × 10−54
PAEP 5047 7,444.75 7.11 0.96 1.70 × 10−13 2.45 × 10−12
CP 1356 307.65 7.01 0.69 1.38 × 10−24 8.39 × 10−23
C2CD4B 388125 59.15 6.66 0.54 6.42 × 10−35 1.25 × 10−32
IRX3 79191 99.72 6.32 0.53 1.90 × 10−32 2.77 × 10−30
BEST1 7439 801.46 6.23 0.76 2.40 × 10−16 5.15 × 10−15
DSEL 92126 88.53 6.12 0.25 4.36 × 10−128 3.05 × 10−124
B4GALNT3 283358 83.11 5.85 0.51 2.80 × 10−30 3.32 × 10−28
PGR 5241 62.02 5.85 0.49 3.04 × 10−33 4.90 × 10−31
ZNF623 9831 59.42 5.77 0.18 1.30 × 10−214 1.82 × 10−210
KIAA1324 57535 79.48 5.58 0.46 1.77 × 10−33 3.03 × 10−31
IGFBP7 3490 658.18 5.52 0.46 3.03 × 10−33 4.90 × 10−31
RORC 6097 36.06 5.47 0.43 3.04 × 10−36 6.86 × 10−34
DEFB1 1672 47.01 5.44 0.58 5.59 × 10−21 2.16 × 10−19
PKHD1 5314 74.85 5.36 0.71 5.31 × 10−14 8.23 × 10−13
ADCY1 107 53.12 5.33 0.37 6.31 × 10−48 2.95 × 10−45
MAPT 4137 23.64 5.30 0.48 4.39 × 10−28 4.15 × 10−26
PRUNE2 158471 140.93 5.29 0.49 9.85 × 10−27 7.89 × 10−25
GALNT15 117248 23.91 5.18 0.47 8.01 × 10−28 7.28 × 10−26
WDR38 401551 74.42 5.12 1.02 5.62 × 10−07 2.74 × 10−06
HAPLN1 1404 3,248.02 −3.66 0.31 1.18 × 10−32 1.80 × 10−30
CD36 948 2,906.67 −3.71 0.39 6.13 × 10−22 2.71 × 10−20
WNT2 7472 1,855.95 −3.72 0.33 8.29 × 10−29 8.30 × 10−27
EGFL6 25975 4,141.42 −3.75 0.29 1.50 × 10−37 3.69 × 10−35
BMP5 653 1,150.58 −3.86 0.37 3.40 × 10−25 2.29 × 10−23
F13A1 2162 7,493.03 −3.98 0.41 1.75 × 10−22 8.18 × 10−21
SPP1 6696 37,734.38 −4.02 0.41 6.04 × 10−23 2.97 × 10−21
HBG2 3048 4,458.52 −4.05 0.38 4.57 × 10−26 3.35 × 10−24
MFSD14A 64645 776.11 −4.19 0.26 5.42 × 10−59 5.96 × 10−56
CSH2 1443 61,726.09 −4.23 0.81 1.94 × 10−07 1.03 × 10−06
AGTR1 185 664.42 −4.27 0.38 2.85 × 10−29 3.03 × 10−27
COX4I2 84701 131.49 −4.28 0.47 1.36 × 10−19 4.47 × 10−18
SVEP1 79987 15,505.08 −4.33 0.46 5.20 × 10−21 2.01 × 10−19
LYVE1 10894 2,663.78 −4.56 0.34 6.68 × 10−42 2.23 × 10−39
CSH1 1442 87,798.80 −4.58 0.67 5.61 × 10−12 6.40 × 10−11
AREG 374 710.42 −4.64 0.45 4.88 × 10−25 3.19 × 10−23
SPESP1 246777 321.55 −5.11 0.40 1.75 × 10−36 4.01 × 10−34
RPS10 6204 742.05 −5.28 0.44 3.32 × 10−33 5.29 × 10−31
CSHL1 1444 2,846.50 −5.43 0.41 2.25 × 10−40 6.85 × 10−38
ZC3H11A 9877 2,887.90 −5.95 0.32 4.7 × 10−76 8.29 × 10−73
Placenta-specific genes are depicted with bold blue. False discovery rate, pFDR; fold change, FC; log fold change
standard error, lfcSE.
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Since majority of these placenta-specific genes are most highly expressed in the trophoblast,
we wished to learn whether their differential expression may reflect alterations in developmental or
functional processes of the trophoblast. Therefore, we examined whether genes involved in villous
trophoblast differentiation [19] (Figure 2A) are enriched among molar DE genes. However, we found
only minimal enrichment (OR = 1.15, p = 0.006).
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Figure 2. Venn diagrams of gene enrichment in complete hydatidiform moles. (A) Overlap between
genes differentially expressed (DE) in complete hydatidiform moles (CHMs; MoleDE), and genes
previously shown to have specific expression in the placenta (PPE) or during villous trophoblast
differentiation (TBDE). (B) Overlap between genes DE in CHMs and previously described imprinted
genes (Imprinted). (C) Overlap between genes DE in CHMs and genes previously shown to be involved
in immune-related processes (Immune).
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TET3, which was up-regulated, plays a key role in epigen tic reprogramming of the zygotic paternal
DNA [21]. All four histone (lysine) demethylases [22] wer up-regulated. In addition, there was a
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enrichment of genes impacted by parental imprinting (Supplementary Table S3, Figure 2B) among DE
genes (OR = 2.38, p = 1.54 × 10−6).
Of note, the DE gene list contained 379 genes involved in immune-related functions (Supplementary
Table S4, Figure 2C), of which 278 (73%) were overexpressed in CHMs. Genes contributing to this
enrichment (OR = 1.82, p = 7.34 × 10−18) included those encoding several cytokines, chemokines and
their receptors (IL1A, interleukin 1 alpha; IL6, IL7, IL8/CXCL8, IL10, IL15, TGFB1, transforming growth
factor beta 1; CXCR2, C-X-C chemokine receptor type 2; CXCR4, IL2RB, IL2RG, IL7R, IL15RA, TGFBR1),
integrins (e.g., ITGA5, integrin subunit alpha 5; ITGAE, ITGAL, ITGAX, ITGB7, integrin subunit beta 7),
and galectins (LGALS4, LGALS13, LGALS14).
2.3. Dysregulated Biological Processes and Pathways in CHMs
Use of iPathwayGuide to investigate biological processes and pathways dysregulated in CHMs
revealed that among 665 gene ontology (GO) biological processes, the most impacted were “cell
adhesion”, “biological adhesion”, “multicellular organismal process”, and “signaling” (Supplementary
Table S5). Applying Elim pruning that iteratively removes genes mapped to a significant GO term
from more general higher level GO terms, identified “calcium ion binding”, “growth factor activity”,
“extracellular matrix structural constituent”, and “G protein-coupled receptor activity” to be the most
impacted among 150 dysregulated biological processes (Table 4, Supplementary Table S6).
Table 4. Twenty most impacted Gene Ontology biological processes in complete hydatidiform moles.
GO ID GO Name Count DE Count All p Elim Pruning
GO:0005509 calcium ion binding 178 426 1.60 × 10−13
GO:0008083 growth factor activity 50 84 5.50 × 10−11
GO:0005201 extracellular matrix structural constituent 74 130 3.00 × 10−08
GO:0004930 G protein-coupled receptor activity 90 188 9.00 × 10−07
GO:0008201 heparin binding 47 99 2.40 × 10−06
GO:0005125 cytokine activity 36 70 3.60 × 10−06
GO:0030020 extracellular matrix structural constituent conferringtensile strength 22 35 4.00 × 10−06
GO:0004888 transmembrane signaling receptor activity 192 421 4.80 × 10−06
GO:0042605 peptide antigen binding 13 17 1.70 × 10−05
GO:0039706 co-receptor binding 8 8 1.90 × 10−05
GO:0005178 integrin binding 42 91 2.00 × 10−05
GO:0005044 scavenger receptor activity 24 43 2.60 × 10−05
GO:0038023 signaling receptor activity 259 568 3.10 × 10−05
GO:0005249 voltage-gated potassium channel activity 23 27 3.70 × 10−05
GO:0004252 serine-type endopeptidase activity 30 60 4.60 × 10−05
GO:0005179 hormone activity 19 34 1.80 × 10−04
GO:0008331 high voltage-gated calcium channel activity 6 6 2.90 × 10−04
GO:0020037 heme binding 29 63 3.90 × 10−04
GO:0030506 ankyrin binding 10 14 4.40 × 10−04
GO:0003996 acyl-CoA ligase activity 7 8 4.40 × 10−04
Differentially expressed, DE; Gene Ontology, GO.
We found the most impacted GO molecular functions to be “signaling receptor activity”, “molecular
transducer activity”, and “gated channel activity” among 105 dysregulated molecular functions
(Supplementary Table S7). Applying Elim pruning, “regulation of signaling receptor activity”, “cell
adhesion”, “chemical synaptic transmission”, and “extracellular matrix organization” were identified
as the most impacted among 628 dysregulated molecular functions (Table 5, Supplementary Table S8).
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Table 5. Twenty most impacted Gene Ontology molecular functions in complete hydatidiform moles.
GO ID GO Name Count DE Count All p Elim Pruning
GO:0010469 regulation of signaling receptor activity 143 285 3.90 × 10−14
GO:0007155 cell adhesion 407 1,014 2.00 × 10−13
GO:0007268 chemical synaptic transmission 165 397 3.60 × 10−07
GO:0030198 extracellular matrix organization 122 271 3.80 × 10−07
GO:0030449 regulation of complement activation 22 33 1.20 × 10−06
GO:0006958 complement activation, classical pathway 16 22 6.40 × 10−06
GO:0034765 regulation of ion transmembrane transport 130 295 1.50 × 10−05
GO:0045669 positive regulation of osteoblast differentiation 29 54 1.50 × 10−05
GO:0007156 homophilic cell adhesion via plasma membraneadhesion molecules 36 76 5.40 × 10−05
GO:0007186 G protein-coupled receptor signaling pathway 196 516 6.00 × 10−05
GO:0007166 cell surface receptor signaling pathway 686 2,116 8.60 × 10−05
GO:0007601 visual perception 51 123 1.50 × 10−04
GO:0006957 complement activation, alternative pathway 8 9 1.50 × 10−04
GO:0006805 xenobiotic metabolic process 32 68 1.60 × 10−04
GO:0002576 platelet degranulation 44 103 1.80 × 10−04
GO:0042102 positive regulation of T cell proliferation 32 60 2.20 × 10−04
GO:0035115 embryonic forelimb morphogenesis 17 29 2.20 × 10−04
GO:0030501 positive regulation of bone mineralization 19 34 2.20 × 10−04
GO:0048662 negative regulation of smooth muscle cellproliferation 23 39 2.30 × 10−04
GO:0035116 embryonic hindlimb morphogenesis 14 22 2.20 × 10−04
Differentially expressed, DE; Gene Ontology, GO.
The most impacted Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways included
“cytokine–cytokine receptor interaction”, “cell adhesion molecules”, “protein digestion and absorption”,
and “neuroactive ligand–receptor interaction”, all important for placental functions (Table 6,
Supplementary Table S9, Figure 3). An unanticipated finding was the most extensive dysregulation of
“cytokine–cytokine receptor interaction” pathway (Figure 4) and “cell adhesion” pathway, both required
for immune cell influx and activation. In addition, representation of 17 immune-related pathways
among 38 dysregulated pathways (Table 6, Supplementary Table S9) reflects a strong immune
component of molar pathogenesis.
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Table 6. Top 20 most impacted pathways in complete hydatidiform moles.
Pathway Name p-value pFDR
Cytokine-cytokine receptor interaction 1.38 × 10−07 2.31 × 10−05
Cell adhesion molecules (CAMs) 1.43 × 10−07 2.31 × 10−05
Protein digestion and absorption 6.20 × 10−07 6.68 × 10−05
Neuroactive ligand-receptor interaction 1.32 × 10−06 1.07 × 10−04
Complement and coagulation cascades 6.91 × 10−06 4.46 × 10−04
Hypertrophic cardiomyopathy (HCM) 1.05 × 10−05 4.87 × 10−04
Extracellular matrix (ECM)-receptor interaction 1.06 × 10−05 4.87 × 10−04
Autoimmune thyroid disease 2.91 × 10−05 1.17 × 10−03
Allograft rejection 7.36 × 10−05 2.39 × 10−03
Graft-versus-host disease 8.01 × 10−05 2.39 × 10−03
Antigen processing and presentation 8.15 × 10−05 2.39 × 10−03
Intestinal immune network for IgA production 9.94 × 10−05 2.68 × 10−03
Staphylococcus aureus infection 1.18 × 10−04 2.94 × 10−03
Metabolism of xenobiotics by cytochrome P450 1.64 × 10−04 3.63 × 10−03
Hematopoietic cell lineage 1.73 × 10−04 3.63 × 10−03
Immune-related pathways are shown in bold blue. False discovery rate, pFDR.
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Figure 3. Pathways perturbation vs. over-representation in complete hydatidiform moles. Pathways are
plotted according to two types of evidence computed by iPathwayGuide: over-representation on the
x-axis (pORA) and the total pathway accumulation on the y-axis (pAcc). For both measures p-values
are displayed on the negative log (base 10) scale. Extr cellular matrix, ECM; human papilloma virus,
HPV; Janus kinase, JAK; signal transducer and activator of transcription, STAT.
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2.4. Validation of RNA-Seq Results at the Protein Level
First, we immunostained TMA slides for cyclin-dependent kinase inhibitor p57 (p57) expression
to confirm the histopathology diagnosis of CHM at the molecular level. Out of 26 samples with
the histopathology diagnosis of CHM, we detected cytotrophoblastic p57 staining in three samples,
while 23 (88%) samples were devoid of p57 expression (Supplementary Figure S1), confirming
the histopathological diagnosis of CHM in 23 samples. For validation of RNA-level findings, we
conducted immunostaining of galectin-14 (gal-14), which is encoded by LGALS14, one of the genes
most down-regulated in CH s according to our RNA-Seq study. Average gal-14 immunoscores were
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43% lower in CHMs than in gestational age-matched controls (1.47 ± 0.08 and 2.60 ± 0.06, respectively,
p < 0.001). Additionally, the percentage of low-intensity staining (1+) was higher in molar than in
control tissues (58% and 3%, respectively), while the percentage of high-intensity staining (3+) was
lower in molar than in control tissues (6% and 61%, respectively), resulting in a significant difference in
the distribution of gal-14 immunoscores (p < 0.001), consistent with RNA-Seq results for this locus
(Figure 5).
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Figure 5. Differential expression of galectin-14 in syncytiotrophoblast in complete hydatidiform
moles and first trimester control placentas. Five-µm-thick first trimester placental sections from
normal pregnancy (A) or from CHMs (B) were stained for galectin-14 (gal-14). Chorionic villi
exhibited intense syncytiotrophoblast cytoplasmic staining (arrows), while the villus stroma and
cytotrophoblasts were negative (arrowheads) in normal placentas, and the syncytiotrophoblast layer
had weak staining in CHMs. Representative images, hematoxylin counterstain, 200×magnifications.
(C) Gal-14 immunoscores (mean ± SEM) and proportion of staining intensities in control placentas
(n = 29) and CHMs (n = 23) are displayed on the left and right graphs, respectively. An unpaired t-test
was used to compare mean immunoscores between control and CHM groups. Fisher’s exact test was
used to test the difference in frequency of gal-14 immunostaining between the two groups. *** p < 0.001.
Cytotrophoblast, CTB; syncytiotrophoblast, STB; villous stroma, VS.
3. Discussion
3.1. Principal Findings of This Study
High-dimensional transcriptomic analysis identified numerous distinctions between CHM and
normal placenta, from which noteworthy patterns can be discerned. (1) the most highly expresse
genes in first trimester normal placentas are those previously shown to have placenta-specific or
predominantly placental expression; (2) in CHMs, overall gene expression levels are higher, while
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expression of placenta-specific transcripts are lower than in first trimester normal placentas; (3) the
pathogenesis of CHMs involves the dysregulation of 27% of protein-coding genes expressed in both
normal placentas and CHMs; (4) most DE genes (72%) in CHMs are up-regulated; (5) placental functions
appear to be down-regulated in CHMs, since placenta-specific genes are enriched in DE genes, and most
are down-regulated; (6) epigenetic reprogramming of the zygotic DNA and parental imprinting is
dysregulated in CHMs; and (7) immune pathways are activated in CHMs as immune-related genes are
enriched in DE genes and 17 immune-related pathways are impacted, mostly up-regulated, among 38
dysregulated pathways.
3.2. Placental Gene Expression and Functions are Down-Regulated in CHMs
In accord with previous studies [17,23], here we found genes with placenta-specific or predominant
placental expression among the most highly expressed genes—12 out of 20—in first trimester normal
placentas. These genes are involved in unique placental functions, including hormones, hormone
synthesizing machinery, proteases, and immune proteins, which are pivotal for placental development,
growth, signaling, and maternal–fetal immune tolerance. In CHMs, however, in spite of the overall
median gene expression level being ~13% higher than in normal first trimester placentas, the overall
median placenta-specific transcript level was 23% lower. This is also substantiated by the lower number
of placenta-specific genes among the 20 most highly expressed transcripts in CHMs.
When investigating differential gene expression, we found 27% of the expressed protein-coding
genes dysregulated in CHMs, of which 72% were up-regulated, underlining the generally higher
gene expression levels in CHMs. Placenta-specific genes were enriched among DE genes, and there
were much more down-regulated (79%) than up-regulated placenta-specific DE genes. In fact, the 20
most down-regulated genes included seven placenta-specific genes, while the 20 most up-regulated
genes were devoid of these. Based on the functions of down-regulated placenta-specific genes, we can
infer that placental growth and development, cell attachment, signaling, and immune defense are the
most highly impacted processes in CHM. This was also supported by the classical pathway analysis,
which revealed among the most impacted GO biological processes “cell adhesion”, “signaling”,
“hormone activity”, “growth factor activity”, and “extracellular matrix structural constituent”, while
the most impacted KEGG pathways included “cell adhesion molecules”, “neuroactive ligand–receptor
interaction”, and “ECM–receptor interaction”.
3.3. Possible Causes of the Dysregulation of Placental Gene Expression in CHMs
Targeted gene expression studies on molar tissues and a recent meta-analysis of these studies
showed that placenta-specific genes involved in villous trophoblast differentiation are also differentially
expressed in molar tissues, and concluded that molar pathogenesis is, indeed, rooted in problems
with trophoblast differentiation [16]. However, these studies were focusing on just a limited set of
placenta-specific transcripts known to be differentially expressed during trophoblast differentiation,
thus did not give a comprehensive insight into this important question. We recently discovered
that abnormal villous trophoblast differentiation is at the root of the pathogenesis of early-onset
preeclampsia, also reflected by profound placental dysregulation of placenta-specific genes [17,19].
Here we applied a similar non-targeted approach to investigate this issue. First, we intersected the
list of DE genes in CHMs with the list of DE genes during villous trophoblast differentiation from
our parallel study [19] and found only minimal enrichment for trophoblast differentiation genes
in dysregulated genes in CHMs, much less than for placenta-specific genes. This suggests that
trophoblast differentiation is moderately affected in CHMs, while the expression of placenta-specific
genes is more extensively impacted. Among the affected placenta-specific genes we validated the
down-regulation of LGALS14 at the protein level. Since histopathological evidence shows the generally
two-layered structure of villous trophoblasts in CHMs as in normal first trimester placentas, in spite of
the histological and molecular evidence of locally more proliferative and or immortalized trophoblasts
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in CHMs [24–31], the histopathology of CHMs also underlines the generally moderate problem with
villous trophoblast differentiation in CHMs.
A more compelling explanation would be that there is a problem with placental gene regulation
due to the changes in DNA methylation and imprinting [32–34] since CHMs only contain paternal
but not maternal genomes [35–37]. To test this hypothesis, we intersected the list of DE genes with
the list of imprinted genes obtained from the GeneImprint database, and we found a significant
enrichment of imprinted genes, underlining the link between CHM pathogenesis and affected paternal
imprinting. In addition, we detected the down-regulation of the de novo DNA methyltransferase
DNMT3A in CHMs, similar to the down-regulation of DNMT3A in absent fetal development, which is
also the characteristics of Dnmt3a or Dnmt3b knockout mice [38]. Moreover, TET3, which is enriched
specifically in the male pronucleus and responsible for paternal-genome conversion of 5mC into
5hmC [21], was two-fold up-regulated in CHMs. This is in good accordance with the paternal origin of
all chromosomes in CHMs. Furthermore, four histone demethylases, which are active in the regulation
of chromatin remodeling and gene expression and in influencing cellular differentiation, development,
tumorigenesis, and inflammatory diseases [22,39], were found to be up-regulated in CHMs. These
findings suggest that the epigenetic reprogramming of the zygotic DNA and parental imprinting are
dysregulated in CHMs.
3.4. Immune Functions are Widely Dysregulated in CHMs
The pathogenesis of familial, biparental hydatidiform moles is caused by the inactivating mutations
of NLRP7 and KHDC3L [40–42], genes involved in imprinting and inflammation. Inactivating mutations
in NLRP7 inhibit cytokine (IL-1, interleukin-1; TNF, tumor necrosis factor) secretion by interfering with
their trafficking, resulting in an in utero environment tolerogenic for the growth of these complete
paternal allografts [41]. In this context, it is important that we found a wide dysregulation of
immune pathways at the maternal–fetal interface in CHMs, which may also be at the heart of disease
pathogenesis. To understand how this would be possible, we need to look first at immune processes
in normal pregnancies. In healthy pregnant women, maternal–fetal immune tolerance mechanisms
are complex and dynamic since embryo implantation in the first trimester is a pro-inflammatory
process at the maternal–fetal interface, while the second trimester brings an anti-inflammatory
milieu for the growing fetus in the womb, and the initiation of parturition at the end of pregnancy
is characterized by a transition back towards a pro-inflammatory state [43–46]. These dynamic
alterations in immune states are driven by the changing placental expression of molecules that regulate
maternal immune responses [47–58]. Importantly, the dysregulated expression of immunoregulatory
molecules at the maternal–fetal interface and the consequent disturbances in maternal–fetal immune
regulation are strongly linked with alterations in the invasiveness of the trophoblast [59,60] and the
development of severe pregnancy complications, such as miscarriages [61–65], preterm labor [66–72],
or preeclampsia [73–79].
Herein, we detected the enrichment of genes involved in immune-related functions among DE
genes in CHMs, and there were much more up-regulated than down-regulated immune-related genes.
Of note, we noticed that IL1A and IL33 were down-regulated while FOXP3 (forkhead box P3), IL7, IL10,
LIF (leukemia inhibitory factor), and TGFB1 were up-regulated, which could theoretically induce a
tolerogenic environment, similarly to familial hydatidiform moles. Indeed, previous studies described
the infiltration of regulatory T cells, CD3+ T cells, and NK cells in CHMs at the implantation site [80–82].
This is in line with the finding herein on the up-regulation of chemokines and the activation of
“cytokine–cytokine receptor interaction” and “cell adhesion molecules” pathways as well as biological
processes such as “cell adhesion”, “biological adhesion”, and “signaling” needed for immune cell
influx and immune responses.
On the other hand, we also detected the down-regulation of LGALS13, LGALS14, the up-regulation
of various HLA-I (A, B, C, E, F, G) and HLA-II (DMA, DMB, DPB1, DRA) genes, complement pathway
genes (e.g., C1S, C3, C5, CR1) and interleukins (e.g., IL6, IL8/CXCL8, IL15, IL16, IL17D), and the overall
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involvement of 17 immune-related pathways among 38 dysregulated pathways. Of note, eight out of
10 (e.g., CD14, CD36, FCGRT, neonatal Fc receptor; LYVE1, lymphatic vessel endothelial hyaluronan
receptor 1) Hofbauer cell marker genes [83] were down-regulated in CHMs in our study in line with the
relative lack of Hofbauer cells in CHM villi [84,85]. These findings suggest an enhanced maternal, over
fetal, antigen-presenting and pro-inflammatory environment at the implantation site, which is also
supported by the activation of the “antigen processing and presentation”, “phagosome”, “complement
and coagulation cascades”, “allograft rejection”, and “graft-versus-host disease” pathways. This is in
line with the fact that CHMs express only paternal antigens and thus represent complete allografts
that could stimulate a vigorous alloimmune response from the maternal host [85], including local
synthesis of complement C3 and complement activation [86]. Not only paternal alloantigens but
also increased necrosis and apoptosis, due to the higher trophoblastic cell proliferation and turnover
rate in CHMs [87,88], may trigger the production of several pro-inflammatory cytokines [89] and the
activation of the complement system [89,90].
Based on all of these findings, we suggest that there is a complex immune dysregulation at
the implantation site in CHMs, which include the parallel induction of anti- and pro-inflammatory
processes due to the presentation of excess paternal antigens, aponecrotic trophoblastic debris, and the
dysregulation of upstream transcription factors and other gene regulatory mechanisms. These are
probably the consequences of abnormal paternal genome dosage and imprinting, resulting in impaired
gene expression and placental development. To delineate the exact sequence of events, one would
need to collect multiple samples from the implantation site in a time-series from patients and controls,
and then to perform the extensive characterization of the localization and expression of RNA and
protein signals. However, this type of sample collection is not possible due to ethical and technical
reasons in spite of the fact that cellular and molecular characterization of such time-series materials
would now be possible using, for example, RNA-Seq after laser capture microdissection or single-cell
RNA-Seq as well as mass spectrometry-based tissue imaging. However, these techniques were not
available for our current study.
3.5. Strengths and Limitations of the Study
According to our knowledge, this is the first non-hypothesis testing study that utilized various tools
of high-dimensional biology to gain in-depth insights into the pathogenesis of CHMs. The strengths of
the study are as follows: (1) strict clinical definitions and homogenous patient groups; (2) standardized,
quick placental sample collection during surgeries and pregnancy terminations; (3) standardized
histopathological examination of molar pregnancies and placentas based on international criteria;
(4) high-quality sample processing and state-of-the-art high-dimensional methods for RNA and protein
level analysis; (5) parallel expression profiling of various proteins on large tissue sets with tissue
microarray and immunostaining followed by semi-quantitative immunoscoring and statistical analysis;
and (6) the use of leading bioinformatics tools for RNA-Seq, gene ontology, and pathway analyses.
Limitations of the study are as follows: (1) the relatively modest number of cases due to the strict
clinical and histopathological inclusion criteria used for patient enrollment. Paradoxically, this was also
one of the most important strengths of our study; (2) data for cases and controls were retrieved from
various sources in the RNA-Seq discovery study; (3) TMAs did not allow us the cellular compositional
analysis of the investigated tissues due to the small core diameter size; and (4) it is possible that the
differences in gene expression levels may originate from differential gene expression of particular cell
types, differential cellular composition of CHMs and normal placentas, or the surgical/methodological
differences in tissue sampling during elective terminations or CHM surgeries.
3.6. Concluding Remarks
In conclusion, our data shows that placental functions are down-regulated, expression of imprinted
genes is altered, and immune pathways are activated in CHMs. Taken together, the results indicate
that complex dysregulation of placental developmental and immune processes are pivotal for the
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pathogenesis of CHMs, providing new biological insight likely to inform molecular translational
research addressing multiple stages of the natural history of CHM, such as assays for improved
detection and refined diagnosis in early pregnancy [91], risk stratification with respect to malignant
potential [92], and differential diagnosis of unexplained pregnancy loss [93].
4. Materials and Methods
4.1. Human Subjects, Clinical Samples, and Definitions
4.1.1. Subjects in the RNA-Seq Discovery Study
All research participants completed a process of informed consent per the University of Southern
California (USC) Health Sciences Institutional Review Board (protocols HS-09-00468 [12 November
2009) and HS-11-00095 (15 June 2011)]. Eligible subjects were identified upon presentation to Los
Angeles County (LAC) and USC Medical Center. CHMs were identified clinically by a combination of
ultrasonographic features (“snowstorm” or “cluster of grapes” appearance) with elevated blood hCG
levels. Molar tissues were obtained between 8 2/7 and 14 0/7 weeks of gestational age by therapeutic
surgical dilation and curettage. Confirmation of CHM diagnosis was determined by the histopathologic
examination of surgical material. One subject who had CHM on the basis of clinical features was
subsequently reclassified as having choriocarcinoma after pathological examination and was excluded
from the study. Another subject with CHM was excluded due to pooling of several samples from
various curettages into one sample, leaving the analyzed number of CHMs at four. Gestational
age-matched control chorionic villous tissues were obtained at the Reproductive Options Clinic at LAC
+ USC Medical Center from surgical elective pregnancy terminations. To increase control group size,
we also obtained RNA-Seq data of first trimester control chorionic villous tissues from a published
study [23] (Table 7).
Table 7. Demographic characteristics of patients in the RNA-Seq discovery study.
Patients Providing GTD Tissue Samples
(n = 4)
Patients Providing Placenta Samples
(n = 40)
Race/ethnicity
Hispanic
Caucasian
Asian
African-American
Unknown/other
2
-
1
-
1
6
34
-
-
-
Age at procedure 25.7 39.2
Histologic diagnosis
Complete mole
Incomplete mole
Invasive mole
3
-
1
-
-
-
Sex chromosome content
XY
XX
-
4
22
18
Gestational age at tissue collection (days) 79.2 (58–98) 84.2 (77–124)
Gestational trophoblastic disease, GTD.
4.1.2. Subjects in the Tissue Microarray Validation Study
GTD tissue samples had been collected during usual care of women who underwent treatment
for GTD at the Department of Obstetrics and Gynecology, Keck School of Medicine, USC (Los Angeles,
CA, USA). After approvals (protocols HS-14-00808 and HS-15-00720 for IRB approval, Lab agreement:
16-03-03) were obtained from the USC IRB, the institutional pathology database at the LAC Medical
Center, Keck Medical Center of USC, and Norris Comprehensive Cancer Center was utilized to identify
GTD cases by searching for the keywords “gestational trophoblastic disease”, “molar pregnancy”,
“hydatidiform mole”, “complete mole”, and “invasive mole” between 1 January 2000 and 11 September
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2017. Inclusion criteria included GTD cases from whom archived histopathology specimens were
available. GTD cases without salient clinical information were excluded.
For eligible GTD cases, data describing clinical and demographic features, tumor characteristics
and markers, treatment course, and survival outcomes were abstracted from the medical record.
Clinical and demographic features included patient age at diagnosis of GTD, ethnicity, pregnancy
history including interval months from the last menstrual period of index pregnancy, body mass
index, and medico-surgical history. Tumor characteristics and markers included the World Health
Organization (WHO) score, histology subtype, tumor size, pretreatment beta-hCG, metastatic sites,
and number. Treatment course included surgical intervention (dilation and curettage, or hysterectomy)
and chemotherapy (type, cycle number, and response). Survival outcomes included progression-free
survival (PFS) and overall survival. Progression-free survival was determined as the time interval
between treatment initiation for GTD and the date of first recurrence or last follow-up date if there was
no recurrence. Overall survival was determined as the time interval between treatment initiation for
GTD and the date of death related to GTD or last follow-up date if the patient was alive.
Of 311 cases that were initially identified, 44 CHM cases were chosen for TMA based on tissue
availability (Tables 8 and 9). We placed no restriction on the age of gestation and found pregnancies to
be dated according to ultrasound scans between 5 and 15 weeks. Patients with multiple pregnancies
were excluded, and specimens and data were de-identified for use in research according to procedures
approved by the Institutional Review Boards of USC. From the 44 GTD tissues identified between 4 2/7
and 36 1/7 weeks of gestational age, the TMA project included 26 samples obtained from therapeutic
surgical dilation and curettage within the first trimester (13 6/7 weeks) and having good tissue quality.
The 26 samples were obtained from 23 patients. One patient provided two specimens at the same
sampling time, while another patient provided three specimens at different time points.
Table 8. Demographic characteristics of patients in the TMA validation study.
Patients Providing GTD Tissue Samples
(n = 23 *)
Patients Providing Placenta Samples
(n = 29)
Race/ethnicity a
Hispanic
Non-Hispanic white
Asian
African-American
Unknown/other
18 (78%)
2 (9%)
0
0
3 (13%)
29 (100%)
Age (years) at procedure b 31.9 ± 9.5 30.4 ± 6.4
Comorbidities
Hypertension a
Diabetes a
beta-hCG (mIU/mL) c
1 (4%)
1 (4%)
185,277
(70,349–387,812)
Histologic diagnosis a
Complete mole 26 (100%) 0 (0%)
p57 immunostaining confirmation of CHM 23 (88%)
Gestational age at the procedure (days) b 64.4 ± 18.2 62.3 ± 11.8
* A total of 26 samples altogether; one case with two specimens at the same time; another case with three specimens
at different time points. a Data are presented as number (percentage). b Data are presented as mean ± SD. c Data are
presented as median (IQR). Cyclin-dependent kinase inhibitor p57; human chorionic gonadotropin, hCG; gestational
trophoblastic disease, GTD; tissue microarray, TMA.
Control samples of first trimester placental tissue (n = 29) matched by gestational age to GTD
samples were collected prospectively at the Maternity Private Clinic (Budapest, Hungary) and deposited
into the Perinatal Biobank of the Research Centre for Natural Sciences, Hungarian Academy of Sciences
(Budapest, Hungary). Informed consent for use of the material in research was obtained from women
prior to sample collection, and specimens and data were stored anonymously. The research was
approved by the Health Science Board of Hungary (TUKEB 4834-0/2011-1018EKU), and all use of tissue
and data in this research conformed to the principles set out in the World Medical Association (WMA)
Declaration of Helsinki. Placentas were collected from pregnancies voluntarily terminated by surgical
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dilation and curettage between 5 and 14 weeks of gestation according to ultrasound scans, excluding
multiple pregnancies (Table 8).
Table 9. Criteria for categorizing gestational trophoblastic disease cases and number of samples in
each category included in the tissue microarray study.
Grouping Definition Sample No. *
1 D&C then cured 15
2a D&C then persistent GTD, cured by first-line single agent 1
2b D&C then persistent GTD, cured by upfront hysterectomy 4
2c D&C then persistent GTD, cured by upfront hysterectomy and adjuvant chemotherapy 0
3a D&C then persistent GTD, received first-line single agent but failed 3
3b D&C then persistent GTD, received first-line multi-agent and cured 0
3c D&C then persistent GTD, received first-line multi-agent and failed 0
3d D&C then persistent GTD, received upfront hysterectomy but recurred 0
4 Recurrent GTD 3
* A total of 26 samples altogether; one case with two specimens at the same time; another case with three specimens
at different time points. Dilatation and curettage, D&C; gestational trophoblastic disease, GTD.
4.2. Experimental Procedures
4.2.1. Sample Collection and Preparation for RNA-Seq
Tissue samples were rinsed with sterile saline and examined under a lightbox for content
confirmation and selection of molar tissue or chorionic villi. Samples were then stored in RNAlater
RNA stabilization reagent (approximately 10 µL reagent per 1mg of tissue, Qiagen, Germantown, MD,
USA) at 37 ◦C for a maximum of 24 h until collected for dissection. Samples were then dissected into
~1 g tissue aliquots and stored at −80 ◦C. Stored samples were then thawed at room temperature and
homogenized with electric homogenizer. Total RNA was isolated using the protocol provided with the
Qiagen RNeasy Mini Kit. RNA quantity was measured by a Nanodrop ND-8000 analyzer (Thermo
Scientific, Waltham, MA, USA). Samples were then stored at −80 ◦C until used.
4.2.2. RNA Sequencing
Library preparation and paired-end sequencing were performed by the USC Epigenome Core
Laboratory. Double-stranded cDNA fragments were synthesized from mRNA, ligated with adapters,
and size-selected for library construction according to Illumina protocol [94]. RNA sequencing was
carried out on Illumina Genome Analyzer (Illumina, San Diego, CA, USA).
4.2.3. Histopathological Examinations
All slides cut from formalin-fixed, paraffin-embedded (FFPE) molar tissue blocks were retrieved
from our USC + LAC histology archives. The slides were reviewed for confirmation of the diagnosis
and regions were identified for TMA construction. The blocks from the matching slides were retrieved
and submitted for TMA construction.
Samples of tissue from first trimester placentas had been fixed in 10% neutral-buffered formalin
and then embedded in paraffin. Five µm sections were cut from tissue blocks, stained with hematoxylin
and eosin (H&E), and examined using light microscopy. A perinatal pathologist blinded to patients’
clinical information, except for the gestational age, examined the histopathology of placental samples
using standard perinatal pathological protocol and previously-published diagnostic criteria [95–97],
and identified regions of each tissue block from which to sample cores.
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4.2.4. Tissue Microarray Construction
A material transfer agreement between the Hungarian Academy of Sciences and USC (No:
1996/2017) enabled the construction of TMAs containing tissues collected at USC and at Maternity
Private Clinic and deposited into the Perinatal Biobank. Four TMAs were constructed, each containing
three cylindrical cores two mm in diameter from each sample of first trimester FFPE placental (n = 29)
or GTD (n = 26) tissue. Cores from the same sample were transferred into recipient paraffin blocks
adjacent to each other using an automated tissue arrayer (TMA Master II, 3DHISTECH, Budapest,
Hungary). Each paraffin block contained three cores from all tissues, with liver included as negative
control and third trimester placenta as positive control material.
4.2.5. Immunohistochemistry and Immunoscoring
To validate the histological diagnosis of CHM, we conducted immunostaining for p57, which is
expressed from a paternally imprinted gene and is a recognized diagnostic marker in CHM [12,98,99].
To validate RNA level findings at the protein level for one down-regulated gene, five-µm-thick sections
were cut from each TMA onto adhesive glass slides (SuperFrost Ultra Plus, TS Labor, Budapest,
Hungary), and immunostained for p57 and galectin-14 using antibodies and conditions listed in
Table 10. Briefly, sections were dewaxed using xylene and rehydrated in graded alcohol series.
Table 10. Immunohistochemistry conditions.
Primary Antibody
(Concentration/Dilution,
Distributor)
Secondary Antibody
(Dilution, Distributor)
Detection Antibody
(Distributor)
Detection System
(Distributor)
monoclonal mouse
anti-human p57 antibody
(1:3000)
(code: MA5-11309,
Thermo Fisher Scientific,
Waltham, MA, USA)
-
Novolink detections
system
(Leica-Novocastra,
Wetzlar, Germany)
Novolink DAB/substrate
kit
(Leica-Novocastra,
Wetzlar, Germany)
recombinant,
His6-tagged anti-human
gal-14 antibody
(0.65 µg/mL)
[provided by Prof. R.
Romero (PRB, NIH)]
monoclonal mouse
anti-His6-tag antibody
(1:200)
(code: 05-959,
Merck-Millipore,
Burlington, MA, USA)
For p57 immunostaining, endogen peroxidases were blocked using 10% H2O2 in methanol
for 20 min, then antigen retrieval was performed in Tris-EDTA pH 9.0 buffer for 20 min at 96 ◦C.
For galectin-14 immunostaining, endogen peroxidases were blocked using 1% H2O2 in methanol for
20 min, then antigen retrieval was performed in Tris-EDTA pH 9.0 buffer for 32 min at 100 ◦C. In all
staining procedure, after 10 min Novolink protein blocking (Leica-Novocastra, Wetzlar, Germany),
the sections were incubated at room temperature with antibodies and then with reagents of the
Novolink Polymer Detection System (Leica-Novocastra). Between incubation steps, the sections
were washed trice for 5 min in Tris-buffered saline (pH 7.4). Finally, sections were counterstained
with hematoxylin, and these were mounted (DPX Mountant; Sigma-Aldrich, St. Louis, MO, USA)
after dehydration.
Immunostained TMA images were semi-quantitatively scored by two examiners blinded to
the clinical information with an immunoreactive score modified from one previously used in our
studies [18,65,74,100–102]. Trophoblastic immunostaining intensity was graded as 0 = negative,
1 = weak, 2 = intermediate, and 3 = strong. For each specimen, all villi and trophoblastic tissues in a
random field of each of the cores were evaluated by both examiners using Panoramic Viewer 1.15.4
(3DHISTECH Ltd., Budapest, Hungary).
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4.3. Data Analysis
4.3.1. Analysis of mRNA Expression (RNA-Seq Data)
For data produced from five samples, FASTQ files were generated by Illumina’s pipeline and
read quality was assessed by FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
Subsequently, reads were submitted to alignment with HISAT2 (v2.1.0) [103]. The mapping was
made using default parameters with reference human genome GRCh38 (downloaded from Illumina
iGenomes). Aligned BAM files were indexed and sorted with Samtools (v0.1.18) [104] for downstream
analysis. Genomic features and read count matrices were obtained using featureCounts (v1.5.2) [105]
based on annotation file hg38 (RefSeq track of UCSC Table Browser).
RNA-Seq count data for additional late first trimester control placentas (22 XY and 17 XX) were
downloaded from GEO (AccNo: GSE109082) [23]. Differential gene expression analysis was performed
using the R package DESeq2 [106,107].
Because data included differing amounts of non-coding RNA leading to high numbers of DE genes
presumed to be spurious, we restricted the differential gene expression analysis to 19,690 protein-coding
genes based on the ENSEMBL “biotype” annotation. We further excluded genes with zero read count
in any sample, resulting in a final analytic set of data on 14,022 genes. As a set of DE transcripts, we
selected those with a fold change of ≥2 between CHM and control, while holding the false discovery
rate (pFDR) to <0.05.
To estimate absolute levels of expression, we normalized RNA-Seq count data by the geometrical
mean of measured counts of four housekeeping genes (TBP, TATA-box binding protein; CYC1,
cytochrome C1; UBC, ubiquitin C; TOP1, topoisomerase (DNA) I), and calculated the mean expression
both in CHM and control groups of samples.
4.3.2. Pathway Analysis
To identify significantly impacted pathways, biological processes, and molecular functions,
we compared expression between CHM and control groups using Advaita Bio’s iPathwayGuide
(https://www.advaitabio.com/ipathwayguide). This software analysis tool implements the “impact
analysis” approach that takes into consideration the direction and type of all signals on a pathway and
the position, role and type of every gene, as described in [108].
4.3.3. Enrichment Analyses
We used Fisher’s exact test to test enrichment of the DE transcript set with genes previously
demonstrated to have expression patterns of particular relevance: (1) genes with placenta-specific
expression (n = 164, Supplementary Table S2) [17]; (2) genes involved in villous trophoblast
differentiation (n = 1,937; GEO: GSE130339, the list was provided by authors of an unpublished
work [19]); (3) genes imprinted in humans (n = 209; imprinted gene databases, www.geneimprint.com,
Supplementary Table S3 and 4 genes related to immune processes (n = 1,449; www.innatedb.com;
the final list is the manual curation and combination of Immport, Immunogenetic Related Information
Source, and Immunome Database Gene Lists, Supplementary Table S4).
4.3.4. Analysis of TMA Data
For each core, immunostain was scored by each of two examiners using a scale of 0 to 3,
0 representing none and 3 strong immunostaining. Quantitative immunoscores were determined
as follows. For each core, immunoscores from examiners were first averaged to represent that core,
and resulting values for each of the three cores representing one sample were averaged to represent that
sample. Mean immunoscores between control and CHM groups were compared using the unpaired
t-test. The Fisher’s exact test was performed to test the distribution of gal-14 immunoscores between
the control and CHM groups. Results were considered statistically significant at * p < 0.05, ** p < 0.01,
and *** p < 0.001.
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4.3.5. Data Availability
USC RNA-Seq data was deposited to the Gene Expression Omnibus (GEO) database according to
the MIAME guidelines (accession number: GSE138250).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/20/
4999/s1.
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ECM extracellular matrix
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KEGG Kyoto Encyclopedia of Genes and Genomes
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References
1. Lurain, J.R. Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis
of gestational trophoblastic disease, and management of hydatidiform mole. Am. J. Obstet. Gynecol. 2010,
203, 531–539. [CrossRef]
2. Garcia-Sayre, J.; Castaneda, A.V.; Roman, L.D.; Matsuo, K. Diagnosis and Management of Gestational
Trophoblastic Disease. In Handbook of Gynecology; Shoupe, D., Ed.; Springer: New York, NY, USA, 2017;
pp. 1–15.
3. Lurain, J.R. Gestational trophoblastic disease II: Classification and management of gestational trophoblastic
neoplasia. Am. J. Obstet. Gynecol. 2011, 204, 11–18. [CrossRef] [PubMed]
4. Seckl, M.J.; Sebire, N.J.; Berkowitz, R.S. Gestational trophoblastic disease. Lancet 2010, 376, 717–729.
[CrossRef]
5. Atrash, H.K.; Hogue, C.J.; Grimes, D.A. Epidemiology of hydatidiform mole during early gestation. Am. J.
Obstet. Gynecol. 1986, 154, 906–909. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 4999 22 of 27
6. Takeuchi, S. Incidence of gestational trophoblastic disease by regional registration in Japan. Hum. Reprod.
1987, 2, 729–734. [CrossRef] [PubMed]
7. Smith, H.O.; Hilgers, R.D.; Bedrick, E.J.; Qualls, C.R.; Wiggins, C.L.; Rayburn, W.F.; Waxman, A.G.;
Stephens, N.D.; Cole, L.W.; Swanson, M.; et al. Ethnic differences at risk for gestational trophoblastic disease
in New Mexico: A 25-year population-based study. Am. J. Obstet. Gynecol. 2003, 188, 357–366. [CrossRef]
[PubMed]
8. Smith, H.O.; Qualls, C.R.; Hilgers, R.D.; Verschraegen, C.F.; Rayburn, W.F.; Cole, L.W.; Padilla, L.A.; Key, C.R.
Gestational trophoblastic neoplasia in American Indians. J. Reprod. Med. 2004, 49, 535–544.
9. Maesta, I.; Berkowitz, R.S.; Goldstein, D.P.; Bernstein, M.R.; Ramirez, L.A.; Horowitz, N.S. Relationship
between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with
low-risk gestational trophoblastic neoplasia. Gynecol. Oncol. 2015, 138, 50–54. [CrossRef]
10. Gockley, A.A.; Joseph, N.T.; Melamed, A.; Sun, S.Y.; Goodwin, B.; Bernstein, M.; Goldstein, D.P.;
Berkowitz, R.S.; Horowitz, N.S. Effect of race/ethnicity on clinical presentation and risk of gestational
trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral
center. Am. J. Obstet. Gynecol. 2016, 215, 334.e1–334.e6. [CrossRef]
11. Sand, P.K.; Lurain, J.R.; Brewer, J.I. Repeat gestational trophoblastic disease. Obstet. Gynecol. 1984, 63,
140–144.
12. Hui, P.; Buza, N.; Murphy, K.M.; Ronnett, B.M. Hydatidiform Moles: Genetic Basis and Precision Diagnosis.
Annu. Rev. Pathol. 2017, 12, 449–485. [CrossRef] [PubMed]
13. Nguyen, N.M.P.; Ge, Z.J.; Reddy, R.; Fahiminiya, S.; Sauthier, P.; Bagga, R.; Sahin, F.I.; Mahadevan, S.;
Osmond, M.; Breguet, M.; et al. Causative Mutations and Mechanism of Androgenetic Hydatidiform Moles.
Am. J. Hum. Genet. 2018, 103, 740–751. [CrossRef] [PubMed]
14. Nguyen, N.M.; Slim, R. Genetics and Epigenetics of Recurrent Hydatidiform Moles: Basic Science and
Genetic Counselling. Curr. Obstet. Gynecol. Rep. 2014, 3, 55–64. [CrossRef] [PubMed]
15. Sanchez-Delgado, M.; Martin-Trujillo, A.; Tayama, C.; Vidal, E.; Esteller, M.; Iglesias-Platas, I.; Deo, N.;
Barney, O.; Maclean, K.; Hata, K.; et al. Absence of Maternal Methylation in Biparental Hydatidiform Moles
from Women with NLRP7 Maternal-Effect Mutations Reveals Widespread Placenta-Specific Imprinting.
PLoS Genet. 2015, 11, e1005644. [CrossRef] [PubMed]
16. Desterke, C.; Slim, R.; Candelier, J.J. A bioinformatics transcriptome meta-analysis highlights the importance
of trophoblast differentiation in the pathology of hydatidiform moles. Placenta 2018, 65, 29–36. [CrossRef]
[PubMed]
17. Than, N.G.; Romero, R.; Tarca, A.L.; Kekesi, K.A.; Xu, Y.; Xu, Z.; Juhasz, K.; Bhatti, G.; Leavitt, R.J.;
Gelencser, Z.; et al. Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways
of Preeclampsia. Front. Immunol. 2018, 9, 1661. [CrossRef] [PubMed]
18. Karaszi, K.; Szabo, S.; Juhasz, K.; Kiraly, P.; Kocsis-Deak, B.; Hargitai, B.; Krenacs, T.; Hupuczi, P.; Erez, O.;
Papp, Z.; et al. Increased placental expression of Placental Protein 5 (PP5) / Tissue Factor Pathway Inhibitor-2
(TFPI-2) in women with preeclampsia and HELLP syndrome: Relevance to impaired trophoblast invasion?
Placenta 2019, 76, 30–39. [CrossRef] [PubMed]
19. Szilagyi, A.; Romero, R.; Xu, Y.; Kiraly, P.; Palhalmi, J.; Gyorffy, B.A.; Juhasz, K.; Hupuczi, P.; Kekesi, K.A.;
Meinhardt, G.; et al. Placenta-specific genes and their regulation during villous trophoblast differentiation.
2019; Submitted.
20. Jia, D.; Jurkowska, R.Z.; Zhang, X.; Jeltsch, A.; Cheng, X. Structure of Dnmt3a bound to Dnmt3L suggests a
model for de novo DNA methylation. Nature 2007, 449, 248–251. [CrossRef]
21. Gu, T.P.; Guo, F.; Yang, H.; Wu, H.P.; Xu, G.F.; Liu, W.; Xie, Z.G.; Shi, L.; He, X.; Jin, S.G.; et al. The role of Tet3
DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011, 477, 606–610. [CrossRef]
22. Nottke, A.; Colaiacovo, M.P.; Shi, Y. Developmental roles of the histone lysine demethylases. Development
2009, 136, 879–889. [CrossRef] [PubMed]
23. Gonzalez, T.L.; Sun, T.; Koeppel, A.F.; Lee, B.; Wang, E.T.; Farber, C.R.; Rich, S.S.; Sundheimer, L.W.;
Buttle, R.A.; Chen, Y.I.; et al. Sex differences in the late first trimester human placenta transcriptome. Biol.
Sex Differ. 2018, 9, 4. [CrossRef] [PubMed]
24. Nishi, H.; Yahata, N.; Ohyashiki, K.; Isaka, K.; Shiraishi, K.; Ohyashiki, J.H.; Toyama, K.; Takayama, M.
Comparison of telomerase activity in normal chorionic villi to trophoblastic diseases. Int. J. Oncol. 1998, 12,
81–85. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 4999 23 of 27
25. Nishi, H.; Ohyashiki, K.; Fujito, A.; Yahata, N.; Ohyashiki, J.H.; Isaka, K.; Takayama, M. Expression of
telomerase subunits and localization of telomerase activation in hydatidiform mole. Placenta 1999, 20,
317–323. [CrossRef]
26. Sebire, N.J.; Lindsay, I. Current issues in the histopathology of gestational trophoblastic tumors. Fetal Pediatr.
Pathol. 2010, 29, 30–44. [CrossRef] [PubMed]
27. Knofler, M.; Pollheimer, J. Human placental trophoblast invasion and differentiation: A particular focus on
Wnt signaling. Front. Genet. 2013, 4, 190. [CrossRef] [PubMed]
28. Buza, N.; Hui, P. Immunohistochemistry and other ancillary techniques in the diagnosis of gestational
trophoblastic diseases. Semin. Diagn. Pathol. 2014, 31, 223–232. [CrossRef]
29. Petts, G.; Fisher, R.A.; Short, D.; Lindsay, I.; Seckl, M.J.; Sebire, N.J. Histopathological and
immunohistochemical features of early hydatidiform mole in relation to subsequent development of
persistent gestational trophoblastic disease. J. Reprod. Med. 2014, 59, 213–220.
30. Fock, V.; Plessl, K.; Fuchs, R.; Dekan, S.; Milla, S.K.; Haider, S.; Fiala, C.; Knofler, M.; Pollheimer, J. Trophoblast
subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete
hydatidiform moles. Hum. Reprod. 2015, 30, 789–799. [CrossRef]
31. Velicky, P.; Meinhardt, G.; Plessl, K.; Vondra, S.; Weiss, T.; Haslinger, P.; Lendl, T.; Aumayr, K.; Mairhofer, M.;
Zhu, X.; et al. Genome amplification and cellular senescence are hallmarks of human placenta development.
PLoS Genet. 2018, 14, e1007698. [CrossRef]
32. Lim, D.H.; Maher, E.R. Human imprinting syndromes. Epigenomics 2009, 1, 347–369. [CrossRef] [PubMed]
33. Ferguson-Smith, A.C. Genomic imprinting: The emergence of an epigenetic paradigm. Nat. Rev. Genet. 2011,
12, 565–575. [CrossRef] [PubMed]
34. Tomizawa, S.; Sasaki, H. Genomic imprinting and its relevance to congenital disease, infertility, molar
pregnancy and induced pluripotent stem cell. J. Hum. Genet. 2012, 57, 84–91. [CrossRef] [PubMed]
35. Fan, J.B.; Surti, U.; Taillon-Miller, P.; Hsie, L.; Kennedy, G.C.; Hoffner, L.; Ryder, T.; Mutch, D.G.; Kwok, P.Y.
Paternal origins of complete hydatidiform moles proven by whole genome single-nucleotide polymorphism
haplotyping. Genomics 2002, 79, 58–62. [CrossRef] [PubMed]
36. Hauzman, E.E.; Papp, Z. Conception without the development of a human being. J. Perinat. Med. 2008, 36,
175–177. [CrossRef]
37. Carey, L.; Nash, B.M.; Wright, D.C. Molecular genetic studies of complete hydatidiform moles. Transl. Pediatr.
2015, 4, 181–188. [PubMed]
38. Gu, H.; Gao, J.; Guo, W.; Zhou, Y.; Kong, Q. The expression of DNA methyltransferases3A is specifically
downregulated in chorionic villi of early embryo growth arrest cases. Mol. Med. Rep. 2017, 16, 591–596.
[CrossRef] [PubMed]
39. Dimitrova, E.; Turberfield, A.H.; Klose, R.J. Histone demethylases in chromatin biology and beyond. EMBO
Rep. 2015, 16, 1620–1639. [CrossRef]
40. Slim, R.; Mehio, A. The genetics of hydatidiform moles: New lights on an ancient disease. Clin. Genet. 2007,
71, 25–34. [CrossRef]
41. Messaed, C.; Akoury, E.; Djuric, U.; Zeng, J.; Saleh, M.; Gilbert, L.; Seoud, M.; Qureshi, S.; Slim, R. NLRP7,
a nucleotide oligomerization domain-like receptor protein, is required for normal cytokine secretion and
co-localizes with Golgi and the microtubule-organizing center. J. Biol. Chem. 2011, 286, 43313–43323.
[CrossRef]
42. Kalogiannidis, I.; Kalinderi, K.; Kalinderis, M.; Miliaras, D.; Tarlatzis, B.; Athanasiadis, A. Recurrent complete
hydatidiform mole: Where we are, is there a safe gestational horizon? Opinion and mini-review. J. Assist.
Reprod. Genet. 2018, 35, 967–973. [CrossRef] [PubMed]
43. Mor, G.; Cardenas, I.; Abrahams, V.; Guller, S. Inflammation and pregnancy: The role of the immune system
at the implantation site. Ann. N. Y. Acad. Sci. 2011, 1221, 80–87. [CrossRef] [PubMed]
44. Racicot, K.; Kwon, J.Y.; Aldo, P.; Silasi, M.; Mor, G. Understanding the complexity of the immune system
during pregnancy. Am. J. Reprod. Immunol. 2014, 72, 107–116. [CrossRef] [PubMed]
45. Aghaeepour, N.; Ganio, E.A.; McIlwain, D.; Tsai, A.S.; Tingle, M.; Van Gassen, S.; Gaudilliere, D.K.; Baca, Q.;
McNeil, L.; Okada, R.; et al. An immune clock of human pregnancy. Sci. Immunol. 2017, 2. [CrossRef]
[PubMed]
46. Fulop, V.; Vermes, G.; Demeter, J. The relationship between inflammatory and immunological processes
during pregnancy. Practical aspects. Orv. Hetil. 2019, 160, 1247–1259. [PubMed]
Int. J. Mol. Sci. 2019, 20, 4999 24 of 27
47. Rusterholz, C.; Hahn, S.; Holzgreve, W. Role of placentally produced inflammatory and regulatory cytokines
in pregnancy and the etiology of preeclampsia. Semin. Immunopathol. 2007, 29, 151–162. [CrossRef] [PubMed]
48. Than, N.G.; Romero, R.; Erez, O.; Weckle, A.; Tarca, A.L.; Hotra, J.; Abbas, A.; Han, Y.M.; Kim, S.S.;
Kusanovic, J.P.; et al. Emergence of hormonal and redox regulation of galectin-1 in placental mammals:
Implication in maternal-fetal immune tolerance. Proc. Natl. Acad. Sci. USA 2008, 105, 15819–15824.
[CrossRef] [PubMed]
49. Than, N.G.; Romero, R.; Goodman, M.; Weckle, A.; Xing, J.; Dong, Z.; Xu, Y.; Tarquini, F.; Szilagyi, A.; Gal, P.;
et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell
death. Proc. Natl. Acad. Sci. USA 2009, 106, 9731–9736. [CrossRef] [PubMed]
50. Hunt, J.S.; Pace, J.L.; Gill, R.M. Immunoregulatory molecules in human placentas: Potential for diverse roles
in pregnancy. Int. J. Dev. Biol. 2010, 54, 457–467. [CrossRef]
51. Than, N.G.; Balogh, A.; Romero, R.; Karpati, E.; Erez, O.; Szilagyi, A.; Kovalszky, I.; Sammar, M.; Gizurarson, S.;
Matko, J.; et al. Placental protein 13 (PP13)—A placental immunoregulatory galectin protecting pregnancy.
Front. Immunol. 2014, 5, 348. [CrossRef]
52. Cheng, S.B.; Sharma, S. Interleukin-10: A pleiotropic regulator in pregnancy. Am. J. Reprod. Immunol. 2015,
73, 487–500. [CrossRef] [PubMed]
53. Than, N.G.; Romero, R.; Balogh, A.; Karpati, E.; Mastrolia, S.A.; Staretz-Chacham, O.; Hahn, S.; Erez, O.;
Papp, Z.; Kim, C.J. Galectins: Double-edged swords in the cross-roads of pregnancy complications and
female reproductive tract inflammation and neoplasia. J. Pathol. Transl. Med. 2015, 49, 181–208. [CrossRef]
[PubMed]
54. Zhang, Y.H.; Tian, M.; Tang, M.X.; Liu, Z.Z.; Liao, A.H. Recent insight into the role of the PD-1/PD-L1
pathway in feto-maternal tolerance and pregnancy. Am. J. Reprod. Immunol. 2015, 74, 201–208. [CrossRef]
[PubMed]
55. Ferreira, L.M.R.; Meissner, T.B.; Tilburgs, T.; Strominger, J.L. HLA-G: At the interface of maternal-fetal
tolerance. Trends Immunol. 2017, 38, 272–286. [CrossRef] [PubMed]
56. Le Bouteiller, P.; Bensussan, A. Up-and-down immunity of pregnancy in humans. F1000Res 2017, 6, 1216.
[CrossRef]
57. Schumacher, A. Human chorionic gonadotropin as a pivotal endocrine immune regulator initiating and
preserving fetal tolerance. Int. J. Mol. Sci. 2017, 18, 2166. [CrossRef]
58. Robertson, S.A.; Care, A.S.; Moldenhauer, L.M. Regulatory T cells in embryo implantation and the immune
response to pregnancy. J. Clin. Investig. 2018, 128, 4224–4235. [CrossRef]
59. Takahashi, H.; Takizawa, T.; Matsubara, S.; Ohkuchi, A.; Kuwata, T.; Usui, R.; Matsumoto, H.; Sato, Y.;
Fujiwara, H.; Okamoto, A.; et al. Extravillous trophoblast cell invasion is promoted by the CD44-hyaluronic
acid interaction. Placenta 2014, 35, 163–170. [CrossRef]
60. Mori, A.; Nishi, H.; Sasaki, T.; Nagamitsu, Y.; Kawaguchi, R.; Okamoto, A.; Kuroda, M.; Isaka, K. HLA-G
expression is regulated by miR-365 in trophoblasts under hypoxic conditions. Placenta 2016, 45, 37–41.
[CrossRef]
61. Raghupathy, R.; Al-Mutawa, E.; Al-Azemi, M.; Makhseed, M.; Azizieh, F.; Szekeres-Bartho, J.
Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women
with recurrent miscarriage or preterm delivery. J. Reprod. Immunol. 2009, 80, 91–99. [CrossRef]
62. Prins, J.R.; Gomez-Lopez, N.; Robertson, S.A. Interleukin-6 in pregnancy and gestational disorders. J. Reprod.
Immunol. 2012, 95, 1–14. [CrossRef] [PubMed]
63. Whitten, A.E.; Romero, R.; Korzeniewski, S.J.; Tarca, A.L.; Schwartz, A.G.; Yeo, L.; Dong, Z.; Hassan, S.S.;
Chaiworapongsa, T. Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous
fibrin deposition (maternal floor infarction): A placental lesion associated with recurrent miscarriage and
fetal death. Am. J. Obstet. Gynecol. 2013, 208, 310.e1–310.e11. [CrossRef] [PubMed]
64. Shemesh, A.; Tirosh, D.; Sheiner, E.; Tirosh, N.B.; Brusilovsky, M.; Segev, R.; Rosental, B.; Porgador, A. First
trimester pregnancy loss and the expression of alternatively spliced NKp30 isoforms in maternal blood and
placental tissue. Front. Immunol. 2015, 6, 189. [CrossRef] [PubMed]
65. Balogh, A.; Toth, E.; Romero, R.; Parej, K.; Csala, D.; Szenasi, N.L.; Hajdu, I.; Juhasz, K.; Kovacs, A.F.; Meiri, H.;
et al. Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response. Front.
Immunol. 2019, 10, 1240. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 4999 25 of 27
66. Romero, R.; Mazor, M.; Brandt, F.; Sepulveda, W.; Avila, C.; Cotton, D.B.; Dinarello, C.A. Interleukin-1 alpha
and interleukin-1 beta in preterm and term human parturition. Am. J. Reprod. Immunol. 1992, 27, 117–123.
[CrossRef] [PubMed]
67. Romero, R.; Mazor, M.; Sepulveda, W.; Avila, C.; Copeland, D.; Williams, J. Tumor necrosis factor in preterm
and term labor. Am. J. Obstet. Gynecol. 1992, 166, 1576–1587. [CrossRef]
68. Cherouny, P.H.; Pankuch, G.A.; Romero, R.; Botti, J.J.; Kuhn, D.C.; Demers, L.M.; Appelbaum, P.C. Neutrophil
attractant/activating peptide-1/interleukin-8: Association with histologic chorioamnionitis, preterm delivery,
and bioactive amniotic fluid leukoattractants. Am. J. Obstet. Gynecol. 1993, 169, 1299–1303. [CrossRef]
69. Gotsch, F.; Romero, R.; Kusanovic, J.P.; Erez, O.; Espinoza, J.; Kim, C.J.; Vaisbuch, E.; Than, N.G.;
Mazaki-Tovi, S.; Chaiworapongsa, T.; et al. The anti-inflammatory limb of the immune response in
preterm labor, intra-amniotic infection/inflammation, and spontaneous parturition at term: A role for
interleukin-10. J. Matern. Fetal Neonatal Med. 2008, 21, 529–547. [CrossRef] [PubMed]
70. Gomez-Lopez, N.; Laresgoiti-Servitje, E.; Olson, D.M.; Estrada-Gutierrez, G.; Vadillo-Ortega, F. The role of
chemokines in term and premature rupture of the fetal membranes: A review. Biol. Reprod. 2010, 82, 809–814.
[CrossRef] [PubMed]
71. Romero, R.; Dey, S.K.; Fisher, S.J. Preterm labor: One syndrome, many causes. Science 2014, 345, 760–765.
[CrossRef] [PubMed]
72. Romero, R.; Grivel, J.C.; Tarca, A.L.; Chaemsaithong, P.; Xu, Z.; Fitzgerald, W.; Hassan, S.S.;
Chaiworapongsa, T.; Margolis, L. Evidence of perturbations of the cytokine network in preterm labor.
Am. J. Obstet. Gynecol. 2015, 213, 836.e1–836.e18. [CrossRef] [PubMed]
73. Than, N.G.; Erez, O.; Wildman, D.E.; Tarca, A.L.; Edwin, S.S.; Abbas, A.; Hotra, J.; Kusanovic, J.P.; Gotsch, F.;
Hassan, S.S.; et al. Severe preeclampsia is characterized by increased placental expression of galectin-1. J.
Matern. Fetal Neonatal Med. 2008, 21, 429–442. [CrossRef] [PubMed]
74. Than, N.G.; Abdul Rahman, O.; Magenheim, R.; Nagy, B.; Fule, T.; Hargitai, B.; Sammar, M.; Hupuczi, P.;
Tarca, A.L.; Szabo, G.; et al. Placental protein 13 (galectin-13) has decreased placental expression but increased
shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP
syndrome. Virchows Arch. 2008, 453, 387–400. [CrossRef] [PubMed]
75. Than, N.G.; Romero, R.; Meiri, H.; Erez, O.; Xu, Y.; Tarquini, F.; Barna, L.; Szilagyi, A.; Ackerman, R.;
Sammar, M.; et al. PP13, maternal ABO blood groups and the risk assessment of pregnancy complications.
PLoS ONE 2011, 6, e21564. [CrossRef] [PubMed]
76. Hsu, P.; Nanan, R.K. Innate and adaptive immune interactions at the fetal-maternal interface in healthy
human pregnancy and pre-eclampsia. Front. Immunol. 2014, 5, 125. [CrossRef]
77. Stoikou, M.; Grimolizzi, F.; Giaglis, S.; Schafer, G.; van Breda, S.V.; Hoesli, I.M.; Lapaire, O.; Huhn, E.A.;
Hasler, P.; Rossi, S.W.; et al. Gestational diabetes mellitus Is associated with altered neutrophil activity. Front.
Immunol. 2017, 8, 702. [CrossRef]
78. Geldenhuys, J.; Rossouw, T.M.; Lombaard, H.A.; Ehlers, M.M.; Kock, M.M. Disruption in the regulation of
immune responses in the placental subtype of preeclampsia. Front. Immunol. 2018, 9, 1659. [CrossRef]
79. Tsuda, S.; Zhang, X.; Hamana, H.; Shima, T.; Ushijima, A.; Tsuda, K.; Muraguchi, A.; Kishi, H.; Saito, S.
Clonally expanded decidual effector regulatory T cells increase in late gestation of normal pregnancy, but
not in preeclampsia, in humans. Front. Immunol. 2018, 9, 1934. [CrossRef]
80. Nagymanyoki, Z.; Callahan, M.J.; Parast, M.M.; Fulop, V.; Mok, S.C.; Berkowitz, R.S. Immune cell profiling
in normal pregnancy, partial and complete molar pregnancy. Gynecol. Oncol. 2007, 107, 292–297. [CrossRef]
81. Hussein, M.R.; Abd-Elwahed, A.R.; Abodeif, E.S.; Abdulwahed, S.R. Decidual immune cell infiltrate in
hydatidiform mole. Cancer Investig. 2009, 27, 60–66. [CrossRef]
82. Sundara, Y.T.; Jordanova, E.S.; Hernowo, B.S.; Gandamihardja, S.; Fleuren, G.J. Decidual infiltration of
FoxP3(+) regulatory T cells, CD3(+) T cells, CD56(+) decidual natural killer cells and Ki-67 trophoblast
cells in hydatidiform mole compared to normal and ectopic pregnancies. Mol. Med. Rep. 2012, 5, 275–281.
[CrossRef] [PubMed]
83. Suryawanshi, H.; Morozov, P.; Straus, A.; Sahasrabudhe, N.; Max, K.E.A.; Garzia, A.; Kustagi, M.; Tuschl, T.;
Williams, Z. A single-cell survey of the human first-trimester placenta and decidua. Sci. Adv. 2018, 4,
eaau4788. [CrossRef] [PubMed]
84. Driscoll, S.G. Trophoblastic growths: Morphologic aspects and taxonomy. J. Reprod. Med. 1981, 26, 181–191.
[PubMed]
Int. J. Mol. Sci. 2019, 20, 4999 26 of 27
85. Berkowitz, R.S.; Faris, H.M.; Hill, J.A.; Anderson, D.J. Localization of leukocytes and cytokines in chorionic
villi of normal placentas and complete hydatidiform moles. Gynecol. Oncol. 1990, 37, 396–400. [CrossRef]
86. Sacks, S.H.; Chowdhury, P.; Zhou, W. Role of the complement system in rejection. Curr. Opin. Immunol. 2003,
15, 487–492. [CrossRef]
87. Qiao, S.; Nagasaka, T.; Harada, T.; Nakashima, N. p53, Bax and Bcl-2 expression, and apoptosis in gestational
trophoblast of complete hydatidiform mole. Placenta 1998, 19, 361–369. [CrossRef]
88. Wargasetia, T.L.; Shahib, N.; Martaadisoebrata, D.; Dhianawaty, D.; Hernowo, B. Characterization of apoptosis
and autophagy through Bcl-2 and Beclin-1 immunoexpression in gestational trophoblastic disease. Iran. J.
Reprod. Med. 2015, 13, 413–420.
89. Davidovich, P.; Kearney, C.J.; Martin, S.J. Inflammatory outcomes of apoptosis, necrosis and necroptosis.
Biol. Chem. 2014, 395, 1163–1171. [CrossRef]
90. Fishelson, Z.; Attali, G.; Mevorach, D. Complement and apoptosis. Mol. Immunol. 2001, 38, 207–219.
[CrossRef]
91. Ronnett, B.M. Hydatidiform Moles: Ancillary Techniques to Refine Diagnosis. Arch. Pathol. Lab. Med. 2018,
142, 1485–1502. [CrossRef]
92. Ning, F.; Hou, H.; Morse, A.N.; Lash, G.E. Understanding and management of gestational trophoblastic
disease. F1000Res 2019, 8, 1–8. [CrossRef] [PubMed]
93. Colley, E.; Hamilton, S.; Smith, P.; Morgan, N.V.; Coomarasamy, A.; Allen, S. Potential genetic causes of
miscarriage in euploid pregnancies: A systematic review. Hum. Reprod. Update 2019, 25, 452–472. [CrossRef]
[PubMed]
94. Meyer, M.; Kircher, M. Illumina sequencing library preparation for highly multiplexed target capture and
sequencing. Cold Spring Harb. Protoc. 2010, 2010, pdb prot5448. [CrossRef]
95. Hargitai, B.; Marton, T.; Cox, P.M. Best practice no 178. Examination of the human placenta. J. Clin. Pathol.
2004, 57, 785–792. [CrossRef] [PubMed]
96. Redline, R.W. Placental pathology: A systematic approach with clinical correlations. Placenta 2008, 29 Suppl.
A, 86–91. [CrossRef]
97. Khong, T.Y.; Mooney, E.E.; Ariel, I.; Balmus, N.C.; Boyd, T.K.; Brundler, M.A.; Derricott, H.; Evans, M.J.;
Faye-Petersen, O.M.; Gillan, J.E.; et al. Sampling and Definitions of Placental Lesions: Amsterdam Placental
Workshop Group Consensus Statement. Arch. Pathol. Lab. Med. 2016, 140, 698–713. [CrossRef]
98. Soma, H.; Osawa, H.; Oguro, T.; Yoshihama, I.; Fujita, K.; Mineo, S.; Kudo, M.; Tanaka, K.; Akita, M.; Urabe, S.;
et al. P57kip2 immunohistochemical expression and ultrastructural findings of gestational trophoblastic
disease and related disorders. Med. Mol. Morphol. 2007, 40, 95–102. [CrossRef]
99. Madi, J.M.; Braga, A.; Paganella, M.P.; Litvin, I.E.; Wendland, E.M. Accuracy of p57(KIP)(2) compared with
genotyping to diagnose complete hydatidiform mole: A systematic review and meta-analysis. BJOG 2018,
125, 1226–1233. [CrossRef]
100. Szabo, S.; Xu, Y.; Romero, R.; Fule, T.; Karaszi, K.; Bhatti, G.; Varkonyi, T.; Varkonyi, I.; Krenacs, T.; Dong, Z.;
et al. Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. Virchows Arch.
2013, 463, 445–458. [CrossRef]
101. Szabo, S.; Mody, M.; Romero, R.; Xu, Y.; Karaszi, K.; Mihalik, N.; Xu, Z.; Bhatti, G.; Fule, T.; Hupuczi, P.; et al.
Activation of villous trophoblastic p38 and ERK1/2 signaling pathways in preterm preeclampsia and HELLP
syndrome. Pathol. Oncol. Res. 2015, 21, 659–668. [CrossRef]
102. Szenasi, N.L.; Toth, E.; Balogh, A.; Juhasz, K.; Karaszi, K.; Ozohanics, O.; Gelencser, Z.; Kiraly, P.; Hargitai, B.;
Drahos, L.; et al. Proteomic identification of membrane-associated placental protein 4 (MP4) as perlecan
and characterization of its placental expression in normal and pathologic pregnancies. PeerJ 2019, 7, e6982.
[CrossRef] [PubMed]
103. Kim, D.; Langmead, B.; Salzberg, S.L. HISAT: A fast spliced aligner with low memory requirements. Nat.
Methods 2015, 12, 357–360. [CrossRef] [PubMed]
104. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R.; Genome
Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009,
25, 2078–2079. [CrossRef] [PubMed]
105. Liao, Y.; Smyth, G.K.; Shi, W. featureCounts: An efficient general purpose program for assigning sequence
reads to genomic features. Bioinformatics 2014, 30, 923–930. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 4999 27 of 27
106. Anders, S.; Huber, W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11, R106.
[CrossRef]
107. Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data
with DESeq2. Genome Biol. 2014, 15, 550. [CrossRef]
108. Draghici, S.; Khatri, P.; Tarca, A.L.; Amin, K.; Done, A.; Voichita, C.; Georgescu, C.; Romero, R. A systems
biology approach for pathway level analysis. Genome Res. 2007, 17, 1537–1545. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
